Alarmins: awaiting a clinical response.
暂无分享,去创建一个
K. Tracey | M. Feldmann | T. Vogl | N. Horwood | J. Chan | J. Nanchahal | J. Roth | J. Oppenheim | J. Roth
[1] M. Bustin,et al. High-mobility group nucleosome-binding protein 1 acts as an alarmin and is critical for lipopolysaccharide-induced immune responses , 2012, The Journal of experimental medicine.
[2] L. Jørgensen,et al. S100A8/A9 deficiency in nonhealing venous leg ulcers uncovered by multiplexed antibody microarray profiling , 2011, The British journal of dermatology.
[3] F. Broere,et al. Heat shock proteins are no DAMPs, rather 'DAMPERs' , 2011, Nature Reviews Immunology.
[4] M. Capogrossi,et al. HMGB1 Attenuates Cardiac Remodelling in the Failing Heart via Enhanced Cardiac Regeneration and miR-206-Mediated Inhibition of TIMP-3 , 2011, PloS one.
[5] Y. Konttinen,et al. Expression of Toll-like Receptors and Their Signaling Pathways in Rheumatoid Synovitis , 2011, The Journal of Rheumatology.
[6] P. Mease. The potential roles for novel biomarkers in rheumatoid arthritis assessment. , 2011, Clinical and experimental rheumatology.
[7] K. Tracey,et al. HMGB1 is a therapeutic target for sterile inflammation and infection. , 2011, Annual review of immunology.
[8] S. Kaveri,et al. Emergence of autoantibodies to HMGB1 is associated with survival in patients with septic shock , 2011, Intensive Care Medicine.
[9] M. Feldmann,et al. TNF-α promotes fracture repair by augmenting the recruitment and differentiation of muscle-derived stromal cells , 2011, Proceedings of the National Academy of Sciences.
[10] Huan Yang,et al. Protective targeting of high mobility group box chromosomal protein 1 in a spontaneous arthritis model. , 2010, Arthritis and rheumatism.
[11] Jay W Fox,et al. Differential proteomic analysis distinguishes tissue repair biomarker signatures in wound exudates obtained from normal healing and chronic wounds. , 2010, Journal of proteome research.
[12] R. Maini,et al. Anti-TNF Therapy, from Rationale to Standard of Care: What Lessons Has It Taught Us? , 2010, The Journal of Immunology.
[13] W. Nacken,et al. The Toll-like receptor 4 ligands Mrp8 and Mrp14 are crucial in the development of autoreactive CD8+ T cells , 2010, Nature Medicine.
[14] J. Gerss,et al. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. , 2010, JAMA.
[15] E. Aronica,et al. Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures , 2010, Nature Medicine.
[16] A. Coyle,et al. HMGB1 and RAGE in inflammation and cancer. , 2010, Annual review of immunology.
[17] M. Bauer,et al. Approaching clinical reality: markers for monitoring systemic inflammation and sepsis. , 2010, Current molecular medicine.
[18] Haichao Wang,et al. High mobility group box 1 protein as a potential drug target for infection- and injury-elicited inflammation. , 2010, Inflammation & allergy drug targets.
[19] M. Boermeester,et al. Expression and role of myeloid-related protein-14 in clinical and experimental sepsis. , 2009, American journal of respiratory and critical care medicine.
[20] E. Matteson,et al. Epitope-specific immunotherapy of rheumatoid arthritis: clinical responsiveness occurs with immune deviation and relies on the expression of a cluster of molecules associated with T cell tolerance in a double-blind, placebo-controlled, pilot phase II trial. , 2009, Arthritis and rheumatism.
[21] M. Feldmann,et al. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis , 2009, Nature Reviews Rheumatology.
[22] D. Foell,et al. The endogenous Toll–like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer , 2009, Journal of leukocyte biology.
[23] T. Wirth,et al. TNFalpha promotes osteogenic differentiation of human mesenchymal stem cells by triggering the NF-kappaB signaling pathway. , 2009, Bone.
[24] A. Sauaia,et al. HMGB1 IS MARKEDLY ELEVATED WITHIN 6 HOURS OF MECHANICAL TRAUMA IN HUMANS , 2009, Shock.
[25] H. Freeze,et al. Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer. , 2009, Neoplasia.
[26] F. Brozzi,et al. S100B's double life: intracellular regulator and extracellular signal. , 2009, Biochimica et biophysica acta.
[27] D. Stroncek,et al. Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer , 2009, Journal of Translational Medicine.
[28] M. Bianchi,et al. Dangers In and Out , 2009, Science.
[29] R. Kang,et al. RAGE (Receptor for Advanced Glycation Endproducts), RAGE Ligands, and their role in Cancer and Inflammation , 2009, Journal of Translational Medicine.
[30] M. Spielmann,et al. Human beta‐defensin‐3 promotes wound healing in infected diabetic wounds , 2009, The journal of gene medicine.
[31] A. Ribas,et al. HMGB1 Mediates Endogenous TLR2 Activation and Brain Tumor Regression , 2009, PLoS medicine.
[32] M. Bianchi,et al. Induction of inflammatory and immune responses by HMGB1–nucleosome complexes: implications for the pathogenesis of SLE , 2008, The Journal of experimental medicine.
[33] R. Landewé,et al. Calprotectin (a major S100 leucocyte protein) predicts 10-year radiographic progression in patients with rheumatoid arthritis , 2008, Annals of the rheumatic diseases.
[34] W. Nacken,et al. Stimulation of chondrocyte-mediated cartilage destruction by S100A8 in experimental murine arthritis. , 2008, Arthritis and rheumatism.
[35] K. Tracey,et al. The HMGB1 Receptor RAGE Mediates Ischemic Brain Damage , 2008, The Journal of Neuroscience.
[36] S. Yamada,et al. Role of high-mobility group box 1 protein in post-infarction healing process and left ventricular remodelling. , 2008, Cardiovascular research.
[37] Hiroyuki Aburatani,et al. The S100A8–serum amyloid A3–TLR4 paracrine cascade establishes a pre-metastatic phase , 2008, Nature Cell Biology.
[38] D. Foell,et al. Proinflammatory S100 Proteins Regulate the Accumulation of Myeloid-Derived Suppressor Cells1 , 2008, The Journal of Immunology.
[39] P. Rovere-Querini,et al. HMGB1: a two-headed signal regulating tumor progression and immunity. , 2008, Current opinion in immunology.
[40] I. Kubota,et al. High-mobility group box 1 restores cardiac function after myocardial infarction in transgenic mice. , 2008, Cardiovascular research.
[41] W. Nacken,et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein , 2008, The Journal of experimental medicine.
[42] S. Coffelt,et al. Tumors sound the alarmin(s). , 2008, Cancer research.
[43] D. Foell,et al. RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis , 2008, Carcinogenesis.
[44] M. Nishibori,et al. Effects of HMGB1 on ischemia-reperfusion injury in the rat heart. , 2008, Circulation journal : official journal of the Japanese Circulation Society.
[45] G. Kollias,et al. Induction of arthritis by high mobility group box chromosomal protein 1 is independent of tumour necrosis factor signalling , 2008, Arthritis research & therapy.
[46] B. Funke,et al. High-Mobility Group Box-1 in Ischemia-Reperfusion Injury of the Heart , 2008, Circulation.
[47] M. Capogrossi,et al. High-mobility group box 1 protein in human and murine skin: involvement in wound healing. , 2008, The Journal of investigative dermatology.
[48] Yi Luo,et al. RDP58 inhibits T cell-mediated bladder inflammation in an autoimmune cystitis model. , 2008, Journal of autoimmunity.
[49] N. Sevenet,et al. Gene profiling in human blood leucocytes during recovery from septic shock , 2008, Intensive Care Medicine.
[50] J. Jones,et al. A review of the S100 proteins in cancer. , 2008, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[51] U. Andersson,et al. Systemic TNF blockade does not modulate synovial expression of the pro-inflammatory mediator HMGB1 in rheumatoid arthritis patients – a prospective clinical study , 2008, Arthritis research & therapy.
[52] T. Ganz,et al. Functional analysis of the host defense peptide Human Beta Defensin-1: new insight into its potential role in cancer. , 2008, Molecular immunology.
[53] T. Yoshino,et al. Anti‐high mobility group box 1 monoclonal antibody ameliorates brain infarction induced by transient ischemia in rats , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[54] M. Bianchi,et al. High‐mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity , 2007, Immunological reviews.
[55] W. Nacken,et al. Myeloid-related proteins S100A8/S100A9 regulate joint inflammation and cartilage destruction during antigen-induced arthritis , 2007, Annals of the rheumatic diseases.
[56] S. Opal,et al. Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection , 2007, Critical care.
[57] J. Roth,et al. New insights in systemic juvenile idiopathic arthritis--from pathophysiology to treatment. , 2007, Rheumatology.
[58] Ruth S. Waterman,et al. Ovarian cancers overexpress the antimicrobial protein hCAP‐18 and its derivative LL‐37 increases ovarian cancer cell proliferation and invasion , 2007, International journal of cancer.
[59] P. Delvenne,et al. Defensins induce the recruitment of dendritic cells in cervical human papillomavirus‐associated (pre)neoplastic lesions formed in vitro and transplanted in vivo , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[60] Laurence Zitvogel,et al. Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy , 2007, Nature Medicine.
[61] W. Nacken,et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock , 2007, Nature Medicine.
[62] M. Omata,et al. Essential roles of high-mobility group box 1 in the development of murine colitis and colitis-associated cancer. , 2007, Biochemical and biophysical research communications.
[63] Herbert J. Zeh,et al. Masquerader: High Mobility Group Box-1 and Cancer , 2007, Clinical Cancer Research.
[64] R. Landewé,et al. Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis , 2007, Annals of the rheumatic diseases.
[65] K. Tracey,et al. High mobility group box‐1 protein induces the migration and activation of human dendritic cells and acts as an alarmin , 2007, Journal of leukocyte biology.
[66] E. Faist,et al. The impact of endogenous triggers on trauma-associated inflammation , 2006, Current opinion in critical care.
[67] P. Angel,et al. S100A8 and S100A9 in inflammation and cancer. , 2006, Biochemical pharmacology.
[68] F. Marshall,et al. Human β-Defensin-1, a Potential Chromosome 8p Tumor Suppressor: Control of Transcription and Induction of Apoptosis in Renal Cell Carcinoma , 2006 .
[69] J. Takeda,et al. Contribution of high-mobility group box-1 to the development of ventilator-induced lung injury. , 2006, American journal of respiratory and critical care medicine.
[70] David C. Lee,et al. ELEVATED HIGH-MOBILITY GROUP BOX 1 LEVELS IN PATIENTS WITH CEREBRAL AND MYOCARDIAL ISCHEMIA , 2006, Shock.
[71] M. Manjili,et al. Comment on “Tumor Progression Can Occur despite the Induction of Very High Levels of Self/Tumor Antigen-Specific CD8+ T Cells in Patients with Melanoma” , 2006, The Journal of Immunology.
[72] K. Tracey,et al. Anti-HMGB1 Neutralizing Antibody Ameliorates Gut Barrier Dysfunction and Improves Survival after Hemorrhagic Shock , 2006, Molecular medicine.
[73] H. Hammes,et al. Inhibition of pathologic retinal neovascularization by α-defensins , 2005 .
[74] D. Foell,et al. Carboxylated Glycans Mediate Colitis through Activation of NF-κB1 , 2005, The Journal of Immunology.
[75] S. Müller,et al. Exogenous High-Mobility Group Box 1 Protein Induces Myocardial Regeneration After Infarction via Enhanced Cardiac C-Kit+ Cell Proliferation and Differentiation , 2005, Circulation research.
[76] C. Hawkey,et al. Rdp58 Is a Novel and Potentially Effective Oral Therapy for Ulcerative Colitis , 2005, Inflammatory bowel diseases.
[77] J. Oppenheim,et al. Alarmins: chemotactic activators of immune responses. , 2005, Current opinion in immunology.
[78] A. Sette,et al. Tolerogenic immune responses to novel T-cell epitopes from heat-shock protein 60 in juvenile idiopathic arthritis , 2005, The Lancet.
[79] Peter P. Nawroth,et al. Release of High Mobility Group Box 1 by Dendritic Cells Controls T Cell Activation via the Receptor for Advanced Glycation End Products1 , 2005, The Journal of Immunology.
[80] M. Keel,et al. Pathophysiology of polytrauma. , 2005, Injury.
[81] Hiroshi Yamamoto,et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. , 2005, The Journal of clinical investigation.
[82] I. Douglas,et al. HMGB1 contributes to the development of acute lung injury after hemorrhage. , 2005, American journal of physiology. Lung cellular and molecular physiology.
[83] B. Sandstedt,et al. Antimicrobial protein hCAP18/LL‐37 is highly expressed in breast cancer and is a putative growth factor for epithelial cells , 2005, International journal of cancer.
[84] K. Tracey,et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion , 2005, The Journal of experimental medicine.
[85] B. Prakken,et al. Heat-shock proteins induce T-cell regulation of chronic inflammation , 2005, Nature Reviews Immunology.
[86] P. Rogalla,et al. Angiogenetic signaling through hypoxia: HMGB1: an angiogenetic switch molecule. , 2005, The American journal of pathology.
[87] Y. Taira,et al. The role of HMGB-1 on the development of necrosis during hepatic ischemia and hepatic ischemia/reperfusion injury in mice. , 2005, The Journal of surgical research.
[88] I. Thorey,et al. MRP8 and MRP14 control microtubule reorganization during transendothelial migration of phagocytes. , 2004, Blood.
[89] K. Clauser,et al. Use of mass spectrometry to identify protein biomarkers of disease severity in the synovial fluid and serum of patients with rheumatoid arthritis. , 2004, Arthritis and rheumatism.
[90] D. Foell,et al. Proinflammatory S100 proteins in arthritis and autoimmune disease. , 2004, Arthritis and rheumatism.
[91] J. Kuja-Panula,et al. Regulation of monocyte migration by amphoterin (HMGB1). , 2004, Blood.
[92] J. Davidson,et al. Migration inhibitory factor‐related protein (MRP)8 and MRP14 are differentially expressed in free‐electron laser and scalpel incisions , 2004, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.
[93] E. Schleicher,et al. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. , 2004, The Journal of clinical investigation.
[94] W. Kuis,et al. CD4+CD25bright Regulatory T Cells Actively Regulate Inflammation in the Joints of Patients with the Remitting Form of Juvenile Idiopathic Arthritis , 2004, The Journal of Immunology.
[95] C. Berry,et al. Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[96] A. Schmidt,et al. S100P Stimulates Cell Proliferation and Survival via Receptor for Activated Glycation End Products (RAGE)* , 2004, Journal of Biological Chemistry.
[97] M. Bianchi,et al. Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation , 2004, The Journal of cell biology.
[98] D. Foell,et al. Methotrexate treatment in juvenile idiopathic arthritis: when is the right time to stop? , 2004, Annals of the rheumatic diseases.
[99] K. Tracey,et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1 , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[100] I. H. Engels,et al. Expression of calcium-binding proteins MRP8 and MRP14 in inflammatory muscle diseases. , 2003, The American journal of pathology.
[101] P. Rouleau,et al. Blockade of S100A8 and S100A9 Suppresses Neutrophil Migration in Response to Lipopolysaccharide 1 , 2003, The Journal of Immunology.
[102] Stefan Joos,et al. HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[103] H. Harris,et al. Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity. , 2003, Arthritis and rheumatism.
[104] B. Bresnihan,et al. Increased perivascular synovial membrane expression of myeloid-related proteins in psoriatic arthritis. , 2003, Arthritis and rheumatism.
[105] S. Zahler,et al. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. , 2003, The Journal of clinical investigation.
[106] O. Rotstein. Modeling the two-hit hypothesis for evaluating strategies to prevent organ injury after shock/resuscitation. , 2003, The Journal of trauma.
[107] D. Foell,et al. S100A12 (EN-RAGE) in monitoring Kawasaki disease , 2003, The Lancet.
[108] A. Bosserhoff,et al. Upregulation of HMG1 Leads to Melanoma Inhibitory Activity Expression in Malignant Melanoma Cells and Contributes to Their Malignancy Phenotype , 2003, Molecular and Cellular Biology.
[109] M. Ståhle-Bäckdahl,et al. The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. , 2003, The Journal of investigative dermatology.
[110] R. Hotchkiss,et al. The pathophysiology and treatment of sepsis. , 2003, The New England journal of medicine.
[111] L. Kwak,et al. Toll-Like Receptor 4-Dependent Activation of Dendritic Cells by β-Defensin 2 , 2002, Science.
[112] W. van Eden,et al. Inhibition of adjuvant-induced arthritis by interleukin-10-driven regulatory cells induced via nasal administration of a peptide analog of an arthritis-related heat-shock protein 60 T cell epitope. , 2002, Arthritis and rheumatism.
[113] S. Sauerland,et al. Association between injury pattern of patients with multiple injuries and circulating levels of soluble tumor necrosis factor receptors, interleukin-6 and interleukin-10, and polymorphonuclear neutrophil elastase. , 2002, The Journal of trauma.
[114] P. Matzinger. The Danger Model: A Renewed Sense of Self , 2002, Science.
[115] Judith Sylvester,et al. Inhibition of interleukin-1-stimulated MAP kinases, activating protein-1 (AP-1) and nuclear factor kappa B (NF-kappa B) transcription factors down-regulates matrix metalloproteinase gene expression in articular chondrocytes. , 2002, Matrix biology : journal of the International Society for Matrix Biology.
[116] L. Kwak,et al. Mediators of Innate Immunity That Target Immature, But Not Mature, Dendritic Cells Induce Antitumor Immunity When Genetically Fused with Nonimmunogenic Tumor Antigens , 2001, The Journal of Immunology.
[117] A. Schmidt,et al. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. , 2001, The Journal of clinical investigation.
[118] T. Kislinger,et al. Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. , 2001, The American journal of pathology.
[119] R. Donato,et al. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. , 2001, The international journal of biochemistry & cell biology.
[120] K. Reinhart,et al. Anti-tumor necrosis factor therapy in sepsis: Update on clinical trials and lessons learned , 2001, Critical care medicine.
[121] A. Varki,et al. Two Proteins Modulating Transendothelial Migration of Leukocytes Recognize Novel Carboxylated Glycans on Endothelial Cells1 , 2001, The Journal of Immunology.
[122] S. Müller,et al. The High Mobility Group (Hmg) Boxes of the Nuclear Protein Hmg1 Induce Chemotaxis and Cytoskeleton Reorganization in Rat Smooth Muscle Cells , 2001, The Journal of cell biology.
[123] D. DeMets,et al. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.
[124] K. Zatloukal,et al. Gene expression patterns associated with the metastatic phenotype in rodent and human tumors. , 2001, Cancer research.
[125] H. Huttunen,et al. Coregulation of Neurite Outgrowth and Cell Survival by Amphoterin and S100 Proteins through Receptor for Advanced Glycation End Products (RAGE) Activation* , 2000, The Journal of Biological Chemistry.
[126] Ji Ming Wang,et al. Ll-37, the Neutrophil Granule–And Epithelial Cell–Derived Cathelicidin, Utilizes Formyl Peptide Receptor–Like 1 (Fprl1) as a Receptor to Chemoattract Human Peripheral Blood Neutrophils, Monocytes, and T Cells , 2000, The Journal of experimental medicine.
[127] K. Tracey,et al. HMG-1 as a mediator of acute lung inflammation. , 2000, Journal of immunology.
[128] N. Wulffraat,et al. Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. , 2000, Arthritis and rheumatism.
[129] H. Huttunen,et al. Regulation of cell migration by amphoterin. , 2000, Journal of cell science.
[130] K. Tracey,et al. HMG-1 as a late mediator of endotoxin lethality in mice. , 1999, Science.
[131] T. Martin. Cytokines and the acute respiratory distress syndrome (ARDS): A question of balance , 1997, Nature Medicine.
[132] R. Jonsson,et al. Measurement of plasma calprotectin as an indicator of arthritis and disease activity in patients with inflammatory rheumatic diseases. , 1994, The Journal of rheumatology.
[133] Kevin J. Tracey,et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia , 1987, Nature.
[134] R. G. Clerc,et al. Two calcium-binding proteins in infiltrate macrophages of rheumatoid arthritis , 1987, Nature.
[135] C. Krettek,et al. Immunomodulation in polytrauma and polymicrobial sepsis - where do we stand? , 2011, Recent patents on inflammation & allergy drug discovery.
[136] Herbert J Zeh,et al. High-mobility group box 1 and cancer. , 2010, Biochimica et biophysica acta.
[137] G. de la Rosa,et al. The alarmin functions of high-mobility group proteins. , 2010, Biochimica et biophysica acta.
[138] Jong Chun Park,et al. TNF-alpha enhances engraftment of mesenchymal stem cells into infarcted myocardium. , 2009, Frontiers in bioscience.
[139] J. Oppenheim,et al. Alarmins and antimicrobial immunity. , 2009, Medical mycology.
[140] M. Bianchi,et al. Regulation of dendritic- and T-cell fate by injury-associated endogenous signals. , 2009, Critical reviews in immunology.
[141] Liwu Li,et al. Macrophages and fibroblasts during inflammation, tissue damage and organ injury. , 2009, Frontiers in bioscience.
[142] R. Bals,et al. The host defence peptide LL-37/hCAP-18 is a growth factor for lung cancer cells. , 2008, Lung cancer.
[143] M. Capogrossi,et al. Pivotal Advance: High-mobility group box 1 protein—a cytokine with a role in cardiac repair , 2006 .
[144] F. Marshall,et al. Human beta-defensin-1, a potential chromosome 8p tumor suppressor: control of transcription and induction of apoptosis in renal cell carcinoma. , 2006, Cancer research.
[145] D. Foell,et al. Carboxylated glycans mediate colitis through activation of NF-kappa B. , 2005, Journal of immunology.
[146] H. Hammes,et al. Inhibition of pathologic retinal neovascularization by alpha-defensins. , 2005, Blood.
[147] Josefina Garcia. Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A , 2004 .
[148] M. Feldmann,et al. Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. , 2003, Nature medicine.
[149] M. Witz. Transected axillary artery: unusual blunt trauma. , 2003, The Journal of trauma.
[150] K Suzuki,et al. TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. , 2001, Nature neuroscience.
[151] M. Polley. Renal transplantation. , 1967, Nursing times.
[152] T. Kislinger,et al. Blockade of RAGE ± amphoterin signalling suppresses tumour growth and metastases , 2022 .